ZyVersa Therapeutics, Inc. (ZVSA) - Dilution Analysis

10-K filing | 8.1M shares outstanding

S-1/A filing: This S-1/A filing relates to the offering and resale by selling stockholders of up to 23,624,938 shares of common stock, including shares that may be issued under an Equity Purchase Agreement and shares issuable upon exercise of Series A-4 warrants.

S-1/A filing: This prospectus relates to the offering and resale by the selling stockholders of up to 23,624,938 shares of our common stock.

8-K filing: ZyVersa Therapeutics, Inc. entered into a warrant exercise inducement offer letter agreement with a holder of outstanding warrants to exercise them for cash at a reduced price of $0.67 per share, in exchange for new warrants, potentially resulting in gross proceeds of approximately $2.05 million for the Company. ($2.05M proceeds)

S-1 filing: This prospectus relates to the offering and resale by Williamsburg Venture Holdings, LLC of up to 17,500,008 shares of our common stock.

10-Q filing | 4.8M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 4,210,530 shares of common stock of ZyVersa Therapeutics, Inc. held by the selling stockholder listed in this prospectus or its permitted transferees.

10-K filing | 2.6M shares outstanding

8-K filing: ZyVersa Therapeutics, Inc. closed a private placement on March 7, 2025, issuing pre-funded warrants to purchase up to 2,105,265 shares and Series A-3 common stock purchase warrants to purchase up to 2,105,265 shares, with gross proceeds of approximately $2 million before deducting fees. ($4.0M proceeds)

S-3 filing: The filing relates to the offer and resale of up to 1,637,000 shares of common stock held by the selling stockholder.

10-Q filing | 2.3M shares outstanding

8-K filing: ZyVersa Therapeutics, Inc. entered into a warrant exercise inducement offer letter agreement with certain holders of outstanding warrants to exercise them for cash at a reduced exercise price of $2.06 per share, in consideration of the Company's agreement to issue new warrants. ($1.7M proceeds)

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 478,600 shares of common stock of ZyVersa Therapeutics, Inc., held by the selling stockholder.

S-3 filing: The filing is an S-3 form indicating the company may offer and sell up to $100,000,000 of common stock, preferred stock, debt securities, purchase contracts and subscription rights in any combination.

10-Q filing | 1.0M shares outstanding

8-K filing: ZyVersa Therapeutics, Inc. entered into a warrant exercise inducement offer letter agreement with a holder of existing warrants to exercise them at a reduced price of $3.46 per share, and in consideration, the Company will issue new warrants to purchase up to 200% of the number of shares issued pursuant to the exercise of the existing warrants. ($0.83M proceeds)

POS AM filing: This prospectus relates to the offer and sale from time to time by ZyVersa Therapeutics, Inc. of up to an aggregate of 586,200 shares of common stock issuable upon exercise of Series A and Series B Warrants.

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 7,594,863 → 759,486

10-K filing | 7.6M shares outstanding

8-K filing: ZyVersa Therapeutics, Inc. closed a public offering on December 11, 2023, issuing 400,000 shares of common stock, 3,600,000 pre-funded warrants, 4,000,000 Series A common warrants, and 4,000,000 Series B common warrants at a combined price of $1.25 per share/warrant, less $0.0001 for each pre-funded warrant.

S-1/A filing: The company is offering up to 3,571,428 shares of common stock, Series A common warrants and Series B common warrants at a combined public offering price of $2.10 per share and accompanying warrants. Also offering pre-funded warrants, each to purchase one share of common stock at an exercise price of $0.0001.

S-1/A filing: The company is offering up to 3,571,428 shares of common stock and warrants to purchase 3,571,428 shares of common stock at an assumed combined price of $2.10 per share and accompanying warrant.

8-K filing: Stock split 1-for-35 | Outstanding: 43,515,401 → 1,243,297

S-1/A filing: S-1/A filing for offering of common stock, pre-funded warrants, and common warrants, with A.G.P./Alliance Global Partners acting as placement agent.

10-Q filing | 43.5M shares outstanding

S-1 filing: S-1 filing for offering of common stock, pre-funded warrants, and common warrants, subject to completion.

S-1/A filing: This S-1/A filing relates to the resale of common stock by selling securityholders, including shares issued in private placements, upon exercise of private and public warrants, and underlying convertible preferred stock.

S-1/A filing: This prospectus relates to the offer and sale from time to time by the Selling Securityholders named in this prospectus of up to 24,647,598 shares of our common stock

8-K filing: ZyVersa Therapeutics, Inc. entered into a warrant exercise inducement offer letter with a holder of warrants to purchase shares of the Company's common stock, where the holder agreed to exercise for cash their Existing Warrants to purchase up to 12,121,213 shares in exchange for new warrants.

10-Q filing | 30.9M shares outstanding

8-K filing: ZyVersa Therapeutics priced and closed a public offering of common stock and warrants, and issued shares in a private placement for extending a lockup period. ($2.1M proceeds)

S-1/A filing: This is an S-1/A filing for a proposed offering of up to 28,571,429 shares of common stock, pre-funded warrants, and warrants, with the net proceeds intended for working capital and general corporate purposes.

S-1/A filing: The filing relates to an offering of common stock, pre-funded warrants, and warrants to purchase common stock, with A.G.P./Alliance Global Partners acting as the placement agent on a reasonable best efforts basis.

10-Q filing | 20.2M shares outstanding

S-1/A filing: S-1/A filing for offering of common stock, pre-funded warrants, and warrants to purchase common stock.

S-1/A filing: This S-1/A filing, dated April 18, 2023, relates to an offering of 8,379,888 shares of common stock, pre-funded warrants to purchase up to 8,379,888 shares of common stock, and warrants to purchase up to 8,379,888 shares of common stock, subject to completion, with A.G.P./Alliance Global Partners as the lead placement agent.

S-1/A filing: This prospectus relates to the offer and sale from time to time by the Selling Securityholders named in this prospectus of up to 15,183,512 shares of our common stock.

S-1/A filing: The company is offering 7,772,020 shares of common stock and warrants to purchase 7,772,020 shares of common stock on a reasonable best efforts basis, with the proceeds to be used primarily to redeem PIPE shares and the remainder for working capital and general corporate purposes; the offering is contingent upon selling enough securities to redeem all PIPE Shares.

10-K filing | 9.0M shares outstanding

S-1/A filing: The company is offering 7,211,538 shares of common stock and warrants to purchase 7,211,538 shares of common stock, as well as pre-funded warrants for investors who would exceed ownership limits.

S-1/A filing: This S-1/A filing, dated February 1, 2023, relates to the offer and sale of up to 15,183,512 shares of common stock by Selling Securityholders, consisting of shares underlying Series A and B Convertible Preferred Stock, and shares issuable upon exercise of private and public warrants.

S-1 filing: This S-1 filing relates to an offering of common stock and warrants, as well as pre-funded warrants and warrants, subject to completion.

S-1 filing: This S-1 filing registers the offer and sale of up to 15,183,512 shares of common stock by selling securityholders, including shares underlying Series A Convertible Preferred Stock, private warrants, Series B Convertible Preferred Stock, and public warrants.

8-K filing: ZyVersa Therapeutics, Inc. consummated a business combination with Larkspur Merger Sub, issued PIPE Warrants and replacement warrants, amended and restated its certificate of incorporation and bylaws, and adopted a new Code of Business Conduct and Ethics.

8-K filing: 7,667,029 shares were tendered for redemption in connection with the stockholders' vote at the Special Meeting held on December 8, 2022.

10-Q filing | 8.1M shares outstanding

10-Q filing | 8.1M shares outstanding

10-Q filing | 8.1M shares outstanding

10-K filing | 8.1M shares outstanding

8-K filing: Larkspur Health Acquisition Corp. consummated its initial public offering of 7,500,000 units at $10.00 per unit, generating gross proceeds of $75,000,000, and simultaneously consummated a private placement of 317,600 units at $10.00 per unit, generating total proceeds of $3,176,000. ($153.18M proceeds)

8-K filing: Larkspur Health Acquisition Corp. completed its initial public offering of 7,500,000 units at $10.00 per unit, generating gross proceeds of $75,000,000, and simultaneously consummated a private placement with Sponsors of 317,600 units at $10.00 per unit, generating total proceeds of $3,176,000. ($78.18M proceeds)

S-1/A filing: This is an S-1/A filing for shares of Class A common stock and redeemable warrants offered as units, including those to be sold in a private placement.

S-1/A filing: This S-1/A filing registers 8,625,000 shares of Class A common stock and 6,468,750 redeemable warrants, including those that may be issued upon exercise of an over-allotment option. The company is offering 7,500,000 units at $10.00 per unit, each consisting of one share of Class A common stock and three-fourths of one redeemable warrant. Additionally, the company will sell 317,600 private units at $10.00 per unit in a private placement that will occur simultaneously with the closing of this offering.

S-1/A filing: This S-1/A filing registers shares of Class A common stock and redeemable warrants as part of units, with an option for the underwriters to cover over-allotments. It details the terms of the offering, including pricing, Nasdaq symbols, trading commencement, and separation of Class A common stock and warrants, along with information on founder shares, private units, redemption rights, and potential risks.

S-1/A filing: This S-1/A filing registers shares of Class A common stock and redeemable warrants as part of units, including an over-allotment option, and covers private placements occurring simultaneously with the offering.

S-1/A filing: This S-1/A filing registers shares of Class A common stock and redeemable warrants to be offered as units, along with private placement shares and warrants, for a special purpose acquisition company.

S-1/A filing: This S-1/A filing registers shares of Class A common stock and redeemable warrants as part of units, including an over-allotment option for underwriters, and discusses the terms, risks, and conditions related to the offering, potential business combinations, and warrant redemption.

S-1 filing: The filing is an S-1 form registering the offering of units, each consisting of one share of Class A common stock and one-half of one redeemable warrant.